After raising $26 million at the start of the year, cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.
After initially setting out to test two vaccines on 28,000 volunteers during West Africa's deadly Ebola epidemic, a U.S.-Liberia research team had to dramatically reduce its aspirations when the outbreak started coming to an end.